Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

吉利德科学公司（Gilead Sciences）与LEO Pharma日前宣布达成战略合作伙伴关系，共同加速LEO Pharma的小分子口服STAT6项目的开发和商业化，旨在为炎症性疾病患者提供潜在治疗方案。

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

据吉利德此前新闻稿介绍，来那帕韦将为对现有疗法无有效应答的HIV感染者提供一种 每年仅需给药两次 的全新治疗方案。 来那帕韦具有300mg片剂和463.5mg/1.5mL注射剂两种剂型，其中 片剂被批准用于治疗起始时口服，取决于起始治疗选项，可在首剂长效来那帕韦注射之前或之时服用 。来那帕韦注射剂只需 每半年皮下注射一次。

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...